News

  • 7 October 2019

    Chi-Med begins new trial for lymphoma treatment

    Hutchison China MediTech (Chi-Med) has commenced a Phase I/Ib clinical trial for the treatment of relapsed or refractory lymphoma patients using its investigational drug candidate HMPL-523.

Close
Close
Close

Go Top